Selektive COX- 2 hæmmere reducerer dannelsen af systemiske (og dermed muligvis endotelderiveret) prostacyclin uden at påvirke thromboxan i blodpladerne.
Selective COX-2 inhibitors reduce the formation of systemic (and therefore possibly endothelial) prostacyclin without affecting platelet thromboxane.